Ethics in Psychedelic Therapy and Research
November 18, 2021
Psychedelic substances like psilocybin, MDMA, and ketamine are increasingly used in research and clinical medicine. By their very nature, they put patients in a vulnerable position. The altered state of consciousness produced by psychedelics can promote insight and healing. However, unscrupulous practitioners can also exploit patients when they are under the influence of these substances. Reports of abuse by licensed and underground psychedelic facilitators highlight these concerns.
On November 18th, ethicists, health care providers, and academic researchers gathered to discuss these risks and broader concerns regarding ethics in psychedelic therapy and research.
Learn more at https://petrieflom.law.harvard.edu/ev...